{"hands_on_practices": [{"introduction": "The success of radiotherapy hinges on maximizing tumor damage while minimizing harm to healthy tissues, a concept known as the therapeutic window. This practice explores the core radiobiological principle that different tissues respond differently to the size of radiation dose per fraction, a property quantified by the $\\alpha/\\beta$ ratio. By calculating the Equivalent Dose in 2 Gy fractions ($EQD2$), you will learn how to compare the biological effects of a given radiation schedule on both a tumor and a critical normal organ, revealing the power of fractionation in clinical practice. [@problem_id:4503436]", "problem": "A patient with locally advanced cervical carcinoma is prescribed pelvic External Beam Radiation Therapy (EBRT) to a total dose of $50.4$ Gray over $28$ daily fractions. Using the Linear-Quadratic (LQ) model, start from the definition of cell survival per fraction and the isoeffect concept to derive a general expression for the Equivalent Dose in $2$ Gray fractions (EQD2) in terms of the Biologically Effective Dose (BED) and the tissue-specific ratio $\\alpha/\\beta$. Then, using tumor $\\alpha/\\beta = 10$ Gray and late-responding rectal tissue $\\alpha/\\beta = 3$ Gray, compute the EQD2 values corresponding to this fractionation for both the tumor and the late rectal tissue. Finally, explain the clinical interpretation of these EQD2 values for tumor control and rectal late effects in the context of gynecologic oncology.\n\nUse the following requirements:\n- Treat the daily fraction size as an unknown $d$ at first principles and then specialize to $d = 50.4/28$.\n- Express the final EQD2 values in Gray (Gy).\n- Round the numerical EQD2 values to three significant figures.\n- Report your two EQD2 values in the order: tumor, rectum.", "solution": "The problem is valid as it is scientifically grounded in the Linear-Quadratic (LQ) model of radiobiology, is well-posed, objective, and contains all necessary information for a unique solution. The parameters and clinical scenario are standard in the field of radiation oncology.\n\nThe solution is approached in three parts: first, the derivation of the general formula for Equivalent Dose in $2$ Gray fractions (EQD2); second, the calculation of EQD2 for the tumor and rectal tissue; and third, the clinical interpretation of the results.\n\nPart 1: Derivation of the EQD2 Formula\n\nThe Linear-Quadratic (LQ) model describes the surviving fraction of cells, $S$, after a single dose of radiation, $d$, as:\n$$S(d) = \\exp(-\\alpha d - \\beta d^2)$$\nwhere $\\alpha$ and $\\beta$ are tissue-specific parameters representing lethal damage from single-hit and two-hit events, respectively.\n\nFor a treatment course consisting of $n$ identical fractions of dose $d$, the total surviving fraction is:\n$$S_{total} = [S(d)]^n = \\exp[-n(\\alpha d + \\beta d^2)]$$\n\nThe total biological effect, $E$, is defined as the natural logarithm of the total cell kill, or equivalently, the negative of the natural logarithm of the total surviving fraction:\n$$E = -\\ln(S_{total}) = n(\\alpha d + \\beta d^2)$$\n\nThe total physical dose delivered is $D = n \\times d$. We can express the number of fractions as $n = D/d$. Substituting this into the equation for the effect $E$:\n$$E = \\frac{D}{d}(\\alpha d + \\beta d^2) = D(\\alpha + \\beta d)$$\n\nThis equation can be rearranged by factoring out the $\\alpha$ parameter to relate the effect to the tissue-specific ratio $\\alpha/\\beta$:\n$$E = \\alpha D \\left(1 + \\frac{d}{\\alpha/\\beta}\\right)$$\n\nThe term $D \\left(1 + \\frac{d}{\\alpha/\\beta}\\right)$ is defined as the Biologically Effective Dose (BED). Thus, the total effect is directly proportional to the BED:\n$$BED = D \\left(1 + \\frac{d}{\\alpha/\\beta}\\right)$$\n$$E = \\alpha \\cdot BED$$\n\nThe principle of isoeffect states that two different fractionation schedules are biologically equivalent if they produce the same total effect, $E$. This implies their BED values must also be equal.\n\nLet us define a radiation schedule (Scheme 1) with total dose $D$, $n$ fractions, and dose per fraction $d$. Its BED is $BED_1 = D \\left(1 + \\frac{d}{\\alpha/\\beta}\\right)$.\nLet us define a reference schedule (Scheme 2) with a dose per fraction of $d_{ref} = 2$ Gy. The total dose for this schedule that yields the same biological effect is called the Equivalent Dose in $2$ Gy fractions, or EQD2. Its BED is $BED_2 = EQD2 \\left(1 + \\frac{2}{\\alpha/\\beta}\\right)$.\n\nApplying the isoeffect principle, $BED_1 = BED_2$:\n$$D \\left(1 + \\frac{d}{\\alpha/\\beta}\\right) = EQD2 \\left(1 + \\frac{2}{\\alpha/\\beta}\\right)$$\n\nThis provides the general expression for EQD2 in terms of the total dose $D$ and dose per fraction $d$:\n$$EQD2 = D \\frac{1 + d/(\\alpha/\\beta)}{1 + 2/(\\alpha/\\beta)}$$\n\nThe problem also asks for an expression for EQD2 in terms of BED. From the isoeffect equation above, we have $BED = EQD2 \\left(1 + \\frac{2}{\\alpha/\\beta}\\right)$. Solving for EQD2, we get:\n$$EQD2 = \\frac{BED}{1 + 2/(\\alpha/\\beta)}$$\nThis equation correctly relates the EQD2 to the BED of any given fractionation schedule for a specific tissue.\n\nPart 2: Calculation of EQD2 for Tumor and Rectum\n\nThe given treatment prescription is a total dose $D = 50.4$ Gray (Gy) delivered in $n = 28$ fractions. The dose per fraction is therefore:\n$$d = \\frac{D}{n} = \\frac{50.4 \\text{ Gy}}{28} = 1.8 \\text{ Gy}$$\n\nWe will now calculate the EQD2 for the tumor and the late-responding rectal tissue using their respective $\\alpha/\\beta$ ratios.\n\nFor the tumor, with $(\\alpha/\\beta)_{tumor} = 10$ Gy:\n$$EQD2_{tumor} = D \\frac{1 + d/(\\alpha/\\beta)_{tumor}}{1 + 2/(\\alpha/\\beta)_{tumor}} = 50.4 \\text{ Gy} \\times \\frac{1 + 1.8/10}{1 + 2/10}$$\n$$EQD2_{tumor} = 50.4 \\times \\frac{1 + 0.18}{1 + 0.2} = 50.4 \\times \\frac{1.18}{1.2} = 49.56 \\text{ Gy}$$\nRounding to three significant figures, $EQD2_{tumor} \\approx 49.6$ Gy.\n\nFor the late-responding rectal tissue, with $(\\alpha/\\beta)_{rectum} = 3$ Gy:\n$$EQD2_{rectum} = D \\frac{1 + d/(\\alpha/\\beta)_{rectum}}{1 + 2/(\\alpha/\\beta)_{rectum}} = 50.4 \\text{ Gy} \\times \\frac{1 + 1.8/3}{1 + 2/3}$$\n$$EQD2_{rectum} = 50.4 \\times \\frac{1 + 0.6}{1 + 2/3} = 50.4 \\times \\frac{1.6}{5/3} = 50.4 \\times \\frac{1.6 \\times 3}{5} = 50.4 \\times 0.96 = 48.384 \\text{ Gy}$$\nRounding to three significant figures, $EQD2_{rectum} \\approx 48.4$ Gy.\n\nPart 3: Clinical Interpretation\n\nThe EQD2 concept is a fundamental tool in radiation oncology for comparing different fractionation schedules on a common biological scale. It represents the total dose that would be required if delivered in standard $2$ Gy fractions to achieve the same biological effect as the schedule in question.\n\nThe calculated EQD2 for the tumor is $49.6$ Gy. This value is slightly less than the prescribed physical dose of $50.4$ Gy. This is because the dose per fraction ($d=1.8$ Gy) is lower than the reference fraction size of $2$ Gy. Tumors, characterized by a high $\\alpha/\\beta$ ratio (typically $\\approx 10$ Gy), are less sensitive to changes in fraction size and their response is more dependent on the total dose. Therefore, the reduction in biological effectiveness is modest.\n\nThe calculated EQD2 for the late-responding rectal tissue is $48.4$ Gy. This value is significantly lower than the physical dose of $50.4$ Gy. Late-responding normal tissues, such as the rectum, are characterized by a low $\\alpha/\\beta$ ratio (typically $\\approx 3$ Gy), which makes them highly sensitive to fraction size. The use of a smaller dose per fraction ($1.8$ Gy) results in a substantial sparing effect on this tissue. The biological damage to the rectum is equivalent to receiving only $48.4$ Gy in $2$ Gy fractions, which implies a lower risk of late toxicity (e.g., chronic proctitis, rectal bleeding, fibrosis) compared to a schedule delivering the same physical dose of $50.4$ Gy in larger fractions (e.g., $2$ Gy fractions, where EQD2 would be $50.4$ Gy).\n\nIn summary, this specific fractionation schedule exploits the radiobiological differences between the tumor and the surrounding healthy late-responding tissue. By using a fraction size smaller than $2$ Gy, it achieves a desirable therapeutic outcome: the biological dose to the tumor is only slightly reduced, while the biological dose to the critical normal tissue (rectum) is reduced more substantially, thus widening the therapeutic window. This enhances the probability of tumor control while minimizing the risk of long-term complications.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n49.6 & 48.4\n\\end{pmatrix}\n}\n$$", "id": "4503436"}, {"introduction": "Delivering a precise dose to a tumor is complicated by uncertainties like patient movement and daily setup variations. To ensure the cancerous tissue is always treated, we create a Planning Target Volume ($PTV$) by adding a margin to the Clinical Target Volume ($CTV$). This exercise demonstrates how to calculate this critical margin using a well-established formula that accounts for both systematic ($\\Sigma$) and random ($\\sigma$) setup errors, translating statistical uncertainty into a concrete geometric volume for treatment planning. [@problem_id:4503445]", "problem": "A patient with locally advanced cervical cancer is treated with pelvic nodal irradiation. The clinical target volume ($CTV$) for nodal regions is to be expanded to a planning target volume ($PTV$) under daily Image-Guided Radiation Therapy (IGRT). Across the treated population, residual setup uncertainties after daily imaging are characterized by a population systematic error $\\Sigma$ of $5$ millimeters and a population random error $\\sigma$ of $3$ millimeters, each assumed isotropic and normally distributed. Using the principle that the $PTV$ margin should ensure that, due to setup uncertainties, at least $95\\%$ of the $CTV$ receives at least $95\\%$ of the prescribed dose in $90\\%$ of patients, derive from first principles the coverage-based margin expression appropriate for three-dimensional translational uncertainties and a realistic dose penumbra, and then compute the single isotropic $CTV \\to PTV$ margin $m$ for this nodal target under daily IGRT. Round your final numerical result to three significant figures and express it in millimeters (mm).", "solution": "The goal is to determine an isotropic expansion $m$ such that the planning target volume ($PTV$) compensates for residual setup uncertainties after daily Image-Guided Radiation Therapy (IGRT), ensuring a coverage criterion: in $90\\%$ of patients, at least $95\\%$ of the clinical target volume ($CTV$) receives at least $95\\%$ of the prescribed dose. The uncertainties are modeled as three-dimensional translational errors with two components: a population systematic error $\\,\\Sigma\\,$ (the standard deviation across patients of the mean setup error) and a population random error $\\,\\sigma\\,$ (the root-mean-square of day-to-day deviations around each patientâ€™s mean setup).\n\nFundamentally, the coverage criterion is formulated by considering the convolution of the dose gradient at the $PTV$ boundary with the distribution of residual setup errors. The cumulative effect of these uncertainties shifts the dose distribution relative to the $CTV$, thereby reducing the minimum dose received by the $CTV$. The systematic component $\\,\\Sigma\\,$ represents patient-specific offsets that persist across fractions, while the random component $\\,\\sigma\\,$ represents fraction-to-fraction variability. For a three-dimensional target with a realistic penumbra width, ensuring that $90\\%$ of patients achieve $95\\%$ $CTV$ coverage at at least $95\\%$ of the prescription leads to a margin that is a linear combination of $\\,\\Sigma\\,$ and $\\,\\sigma\\,$, with coefficients determined by the coverage probability and the penumbral slope.\n\nThe derivation proceeds by:\n1. Modeling the setup error vector as a random variable with a population distribution whose patient-specific mean has standard deviation $\\,\\Sigma\\,$ and whose intra-patient fraction-to-fraction standard deviation is $\\,\\sigma\\,$.\n2. Relating the required margin to the worst-case displacements consistent with the target coverage quantiles. The systematic term dominates the inter-patient variability of the dose coverage, and the random term contributes through the fractionation and the slope of the dose fall-off (penumbra).\n3. Applying the established coverage-based result for three-dimensional translational uncertainties and typical penumbra characteristics, yielding an analytic expression of the form\n$$\nm \\approx a\\,\\Sigma + b\\,\\sigma,\n$$\nwhere $a$ and $b$ are coefficients derived from the coverage goal ($95\\%$ of the $CTV$ receives at least $95\\%$ of dose in $90\\%$ of patients) and the penumbral steepness. For the stated criterion and a realistic three-dimensional dose gradient, the coefficients are\n$$\na = 2.5,\\quad b = 0.7.\n$$\n\nThus, the margin is\n$$\nm \\approx 2.5\\,\\Sigma + 0.7\\,\\sigma.\n$$\n\nSubstituting the given values $\\,\\Sigma = 5\\,\\text{mm}\\,$ and $\\,\\sigma = 3\\,\\text{mm}\\,$ (keeping units outside of symbolic calculations and focusing on the numerical computation at the end), we obtain\n$$\nm \\approx 2.5 \\times 5 + 0.7 \\times 3 = 12.5 + 2.1 = 14.6.\n$$\n\nRounded to three significant figures and expressed in millimeters, the isotropic $CTV \\to PTV$ margin is $14.6\\,\\text{mm}$.", "answer": "$$\\boxed{14.6}$$", "id": "4503445"}, {"introduction": "The definitive treatment of locally advanced gynecologic cancers often involves a powerful combination of External Beam Radiation Therapy (EBRT) and brachytherapy. Since physical doses (in Gray) from different fractionation schemes are not directly additive, we must use radiobiological models to assess the total treatment effect. This problem guides you through calculating the Biologically Effective Dose ($BED$) for each modality and combining them to determine if the comprehensive treatment plan achieves the required therapeutic benchmark, a critical skill for evaluating multi-modality radiotherapy. [@problem_id:4503446]", "problem": "A patient with locally advanced cervical carcinoma is planned for combined External Beam Radiation Therapy (EBRT) and High-Dose-Rate (HDR) brachytherapy to the High-Risk Clinical Target Volume (HR-CTV). EBRT prescribes a pelvic dose of $45$ Gy in $25$ fractions, and HDR brachytherapy prescribes $7$ Gy per fraction for $4$ fractions to the HR-CTV. Assume the tumor radiobiological characteristics follow the linear-quadratic model with a tissue-specific ratio of radiosensitivity parameters $\\alpha/\\beta = 10$ Gy appropriate for early-responding tissues and tumor control. The target for definitive therapy is a minimum Equivalent Dose in $2$ Gy fractions (EQD2) to the HR-CTV of at least $85$ Gy when combining EBRT and brachytherapy, evaluated using $\\alpha/\\beta = 10$ Gy.\n\nStarting from the linear-quadratic description of cell survival for fractionated irradiation and the definition of Biologically Effective Dose (BED) as a measure proportional to the cumulative logarithmic cell kill normalized by $\\alpha$, derive the expressions necessary to compute:\n- the HDR brachytherapy BED to the HR-CTV,\n- the HDR brachytherapy EQD2 to the HR-CTV,\n- the combined EBRT plus HDR brachytherapy EQD2 to the HR-CTV,\n\nall using $\\alpha/\\beta = 10$ Gy. Based on the combined EQD2, determine whether the plan meets the target threshold of $85$ Gy (meeting the target is defined as greater than or equal to the threshold).\n\nReport the final result as a row vector in the order $\\big[$HDR brachytherapy BED, HDR brachytherapy EQD2, combined EQD2, indicator$\\big]$, where the indicator equals $1$ if the combined EQD2 meets or exceeds $85$ Gy and equals $0$ otherwise. Express all doses in Gy. Round all requested numerical outputs to four significant figures.", "solution": "## PROBLEM VALIDATION\n\n### Step 1: Extract Givens\nThe data and conditions explicitly provided in the problem statement are as follows:\n- **Treatment Modality 1 (EBRT)**: Total pelvic dose $D_{EBRT} = 45$ Gy, delivered in $n_{EBRT} = 25$ fractions.\n- **Treatment Modality 2 (HDR Brachytherapy)**: Dose per fraction $d_{HDR} = 7$ Gy, delivered for $n_{HDR} = 4$ fractions.\n- **Target Volume**: High-Risk Clinical Target Volume (HR-CTV).\n- **Radiobiological Model**: Linear-quadratic model.\n- **Tissue-Specific Parameter**: Ratio of radiosensitivity parameters $\\alpha/\\beta = 10$ Gy.\n- **Therapeutic Goal**: Minimum Equivalent Dose in $2$ Gy fractions (EQD2) to the HR-CTV of at least $85$ Gy, evaluated using $\\alpha/\\beta = 10$ Gy.\n- **Task Requirements**:\n    1. Derive necessary expressions for HDR brachytherapy BED, HDR brachytherapy EQD2, and combined EQD2.\n    2. Compute the numerical values for these quantities.\n    3. Determine if the combined EQD2 meets the target threshold of $85$ Gy.\n    4. Report the final results as a row vector: $\\big[$HDR brachytherapy BED, HDR brachytherapy EQD2, combined EQD2, indicator$\\big]$.\n    5. The indicator is $1$ if the combined EQD2 is greater than or equal to $85$ Gy, and $0$ otherwise.\n    6. All dose outputs are to be expressed in Gy and rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed based on the specified validation criteria.\n\n- **Scientifically Grounded (Critical)**: The problem is fundamentally based on the linear-quadratic (LQ) model, which is the standard model in clinical radiobiology for quantifying the effects of fractionated radiotherapy. The concepts of Biologically Effective Dose (BED) and Equivalent Dose in $2$ Gy fractions (EQD2) are direct and standard applications of the LQ model. The dose-fractionation schemes ($45$ Gy in $25$ fractions for EBRT, $7$ Gy x $4$ for HDR brachytherapy) and the $\\alpha/\\beta$ value of $10$ Gy for tumors are clinically realistic and standard for the treatment of locally advanced cervical cancer. The target EQD2 of $85$ Gy is also a well-established clinical benchmark. The problem is scientifically sound.\n\n- **Well-Posed**: All necessary parameters ($D_{EBRT}$, $n_{EBRT}$, $d_{HDR}$, $n_{HDR}$, $\\alpha/\\beta$) are provided. The objectives are clearly defined. The problem structure allows for the calculation of a unique, stable, and meaningful solution.\n\n- **Objective (Critical)**: The problem is stated in precise, quantitative, and unbiased technical language. It does not contain subjective statements or opinions.\n\nThe problem does not exhibit any of the listed invalidity flaws. It is scientifically sound, well-posed, completely formalizable, and based on realistic clinical and physical parameters.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. A detailed solution will be provided.\n\n## SOLUTION\n\nThe solution requires the application of the linear-quadratic (LQ) model to calculate and combine the biological effects of two different radiation therapy courses. We begin by deriving the necessary formalisms.\n\n### Derivation of Biologically Effective Dose (BED)\nThe LQ model describes the surviving fraction of cells, $S$, after a single dose of radiation, $d$, as:\n$$S(d) = \\exp(-(\\alpha d + \\beta d^2))$$\nwhere $\\alpha$ and $\\beta$ are tissue-specific radiosensitivity parameters representing the linear (lethal) and quadratic (sublethal, cumulative) components of cell killing, respectively.\n\nFor a fractionated course of $n$ identical fractions of dose $d$ each, assuming full repair of sublethal damage between fractions, the total surviving fraction is:\n$$S_n = [S(d)]^n = [\\exp(-(\\alpha d + \\beta d^2))]^n = \\exp(-n(\\alpha d + \\beta d^2))$$\nThe total biological effect, denoted as $E$, is proportional to the total log cell kill:\n$$E = -\\ln(S_n) = n(\\alpha d + \\beta d^2)$$\nThe Biologically Effective Dose (BED) is defined as the total biological effect normalized by the linear radiosensitivity coefficient $\\alpha$. This provides a measure of biological damage that is independent of the specific dose-per-fraction details and allows for comparison between different fractionation schemes.\n$$BED = \\frac{E}{\\alpha} = \\frac{n(\\alpha d + \\beta d^2)}{\\alpha} = nd \\left(1 + \\frac{\\beta}{\\alpha}d\\right)$$\nUsing the total physical dose $D = nd$ and the ratio $\\alpha/\\beta$, the formula becomes:\n$$BED = D \\left(1 + \\frac{d}{\\alpha/\\beta}\\right)$$\n\n### Derivation of Equivalent Dose in 2 Gy Fractions (EQD2)\nThe EQD2 is the total physical dose that would deliver the same biological effect (i.e., the same BED) if it were administered in fractions of a standard size, $d_{ref} = 2$ Gy. To find the EQD2 for a given treatment schedule with a calculated BED, we equate the BEDs:\n$$BED_{schedule} = BED_{EQD2}$$\nLet the total EQD2 dose be delivered in $n_2$ fractions of $d_{ref} = 2$ Gy, so $EQD2 = n_2 \\times 2$ Gy. The BED for this reference schedule is:\n$$BED_{EQD2} = EQD2 \\left(1 + \\frac{d_{ref}}{\\alpha/\\beta}\\right) = EQD2 \\left(1 + \\frac{2}{\\alpha/\\beta}\\right)$$\nBy equating $BED_{schedule}$ with $BED_{EQD2}$, we can solve for EQD2:\n$$EQD2 = \\frac{BED_{schedule}}{1 + \\frac{2}{\\alpha/\\beta}} = BED_{schedule} \\left( \\frac{\\alpha/\\beta}{\\alpha/\\beta + 2} \\right)$$\nA crucial property, assuming full repair between treatment courses, is that BED values are additive. Therefore, for a combined treatment of EBRT and HDR brachytherapy, the total BED is the sum of the individual BEDs:\n$$BED_{total} = BED_{EBRT} + BED_{HDR}$$\nThis total BED can then be converted to a total EQD2.\n\n### Calculation of Treatment Parameters\nWe now apply these formulas using the provided data: $\\alpha/\\beta = 10$ Gy.\n\n**1. External Beam Radiation Therapy (EBRT)**\n- Total dose, $D_{EBRT} = 45$ Gy.\n- Number of fractions, $n_{EBRT} = 25$.\n- Dose per fraction, $d_{EBRT} = \\frac{D_{EBRT}}{n_{EBRT}} = \\frac{45}{25} = 1.8$ Gy.\n\nThe BED delivered by EBRT is:\n$$BED_{EBRT} = D_{EBRT} \\left(1 + \\frac{d_{EBRT}}{\\alpha/\\beta}\\right) = 45 \\left(1 + \\frac{1.8}{10}\\right) = 45(1.18) = 53.1 \\text{ Gy}$$\n\n**2. High-Dose-Rate (HDR) Brachytherapy**\n- Number of fractions, $n_{HDR} = 4$.\n- Dose per fraction, $d_{HDR} = 7$ Gy.\n- Total dose, $D_{HDR} = n_{HDR} \\times d_{HDR} = 4 \\times 7 = 28$ Gy.\n\nThe BED delivered by HDR brachytherapy is the first required value:\n$$BED_{HDR} = D_{HDR} \\left(1 + \\frac{d_{HDR}}{\\alpha/\\beta}\\right) = 28 \\left(1 + \\frac{7}{10}\\right) = 28(1.7) = 47.6 \\text{ Gy}$$\nRounding to four significant figures, $BED_{HDR} = 47.60$ Gy.\n\nNow, we compute the EQD2 for the HDR brachytherapy component, which is the second required value:\n$$EQD2_{HDR} = BED_{HDR} \\left( \\frac{\\alpha/\\beta}{\\alpha/\\beta + 2} \\right) = 47.6 \\left( \\frac{10}{10 + 2} \\right) = 47.6 \\left( \\frac{10}{12} \\right) \\approx 39.666... \\text{ Gy}$$\nRounding to four significant figures, $EQD2_{HDR} = 39.67$ Gy.\n\n**3. Combined EBRT + HDR Brachytherapy**\nThe total BED from the combined treatment is the sum of the individual BEDs:\n$$BED_{total} = BED_{EBRT} + BED_{HDR} = 53.1 + 47.6 = 100.7 \\text{ Gy}$$\nThe combined EQD2 for the entire treatment course is the third required value. This is found by converting $BED_{total}$ to its equivalent in $2$ Gy fractions:\n$$EQD2_{total} = BED_{total} \\left( \\frac{\\alpha/\\beta}{\\alpha/\\beta + 2} \\right) = 100.7 \\left( \\frac{10}{10 + 2} \\right) = 100.7 \\left( \\frac{10}{12} \\right) \\approx 83.9166... \\text{ Gy}$$\nRounding to four significant figures, $EQD2_{total} = 83.92$ Gy.\n\n**4. Target Assessment**\nThe fourth required value is the indicator variable, which determines if the plan meets the target threshold.\n- Target EQD2: $\\ge 85$ Gy.\n- Calculated combined EQD2: $83.92$ Gy.\n\nWe compare the calculated value to the threshold:\n$$83.92 \\text{ Gy} < 85 \\text{ Gy}$$\nSince the calculated combined EQD2 does not meet or exceed the target of $85$ Gy, the indicator value is $0$.\n\n### Summary of Results\nThe requested values are:\n- HDR brachytherapy BED: $47.60$ Gy\n- HDR brachytherapy EQD2: $39.67$ Gy\n- Combined EQD2: $83.92$ Gy\n- Indicator: $0$\n\nThese results will be presented in the final answer as a row vector.", "answer": "$$\n\\boxed{\\begin{pmatrix} 47.60 & 39.67 & 83.92 & 0 \\end{pmatrix}}\n$$", "id": "4503446"}]}